Results 61 to 70 of about 29,800 (242)
Toxic Epidermal Necrolysis Associated with Misoprostol: A Case Report
Okbu Frezgi,1 Mulugeta Russom2– 4 1Gynecology and Obstetric Unit, Orotta College of Medicine and Health Sciences, Asmara, Eritrea; 2Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea ...
Frezgi O, Russom M
doaj
Toxic epidermal necrolysis is the most severe form of drug-induced skin reaction and includes denudation of >30% of total body surface area. The mechanism of disease is not completely understood, but immunologic mechanisms, cytotoxic reactions, and ...
Carlos Saavedra+4 more
doaj +1 more source
Primary illness with cytomegalovirus leads to latent infection with possible reactivations especially in the immunocompromised patients. Toxic epidermal necrolysis is an immune mediated cytotoxic reaction.
Dina Khalaf+3 more
doaj +1 more source
Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper
ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini+10 more
wiley +1 more source
Lamotrigine and anti‐seizure medications in HLH: A systematic review
Lamotrigine and other anti‐seizure medications have been reported to cause both haemophagocytic lympho‐histiocytosis (HLH) and drug‐induced hypersensitivity syndrome (DIHS). HLH and DIHS have many characteristic clinical, laboratory, pathological findings and underlying mechanisms; we identified significant clinical overlap between these two syndromes ...
Yaswanta K. Gummadi+4 more
wiley +1 more source
Toxic epidermal necrolysis (TEN) represents the most serious affection within the SCARs group (Severe Cutaneous Adverse Reactions). It is an autoimmune disease manifested by extensive epidermal and mucosal exfoliation.
B. Lipový+8 more
doaj
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source
Objective: To recognize the common ocular signs and symptoms of toxic epidermal necrolysis (TEN), differentiate it from similar diseases, give the appropriate management, and provide continuity of care.
Rosalie Mae M. Reyes, MD+1 more
doaj
Objective: To describe the history of toxic epidermal necrolysis, before and after the original report by the British dermatologist Alan Lyell in 1956. Methods: Subjective expert choice of key advances in the comprehension of the nosology, classification,
Jean-Claude Roujeau
doaj +1 more source
Toxic Epidermal Necrolysis A Diagnostic Dilemma in Puerperium: A Case Report
Toxic epidermal necrolysis is a potentially life threatening dermatologic disorder characterized by widespread erythema, necrosis and bullas, detachment of epidermis and mucous membrane resulting in exfoliation, possible sepsis and even death.
Vidya Mahto +2 more
doaj +1 more source